Gasdermin D-mediated hepatocyte pyroptosis expands inflammatory responses that aggravate acute liver failure by upregulating monocyte chemotactic protein 1/CC chemokine receptor-2 to recruit macrophages

BACKGROUND Massive hepatocyte death is the core event in acute liver failure(ALF).Gasdermin D(GSDMD)-mediated pyroptosis is a type of highly inflammatory cell death.However,the role of hepatocyte pyroptosis and its mechanisms of expanding inflammatory responses in ALF are unclear.AIM To investigate the role and mechanisms of GSDMD-mediated hepatocyte pyroptosis through in vitro and in vivo experiments.METHODS The expression of pyroptosis pathway-associated proteins in liver tissues from ALF patients and a hepatocyte injury model was examined by Western blot.GSDMD short hairpin RNA(shRNA)was used to investigate the effects of downregulation of GSDMD on monocyte chemotactic protein 1(MCP1)and its receptor CC chemokine receptor-2(CCR2)in vitro.For in vivo experiments,we used GSDMD knockout mice to investigate the role and mechanism of GSDMD in a D-galactose/lipopolysaccharide(D-Galn/LPS)-induced ALF mouse model.RESULTS The levels of pyroptosis pathway-associated proteins in liver tissue from ALF patients and a hepatocyte injury model increased significantly.The level of GSDMD-N protein increased most obviously(P<0.001).In vitro,downregulation of GSDMD by shRNA decreased the cell inhibition rate and the levels of MCP1/CCR2 proteins(P<0.01).In vivo,GSDMD knockout dramatically eliminated inflammatory damage in the liver and improved the survival of DGaln/LPS-induced ALF mice(P<0.001).Unlike the mechanism of immune cell pyroptosis that involves releasing interleukin(IL)-1βand IL-18,GSDMDmediated hepatocyte pyroptosis recruited macrophages via MCP1/CCR2 to aggravate hepatocyte death.However,this pathological process was inhibited after knocking down GSDMD.CONCLUSION GSDMD-mediated hepatocyte pyroptosis plays an important role in the pathogenesis of ALF,recruiting macrophages to release inflammatory mediators by upregulating MCP1/CCR2 and leading to expansion of the inflammatory responses.GSDMD knockout can reduce hepatocyte death and inflammatory responses,thus alleviating ALF.

Molecular detection of monocyte chemotactic protein-1 polymorphism in spontaneous bacterial peritonitis patients

AIM: To investigate the association of the functional monocyte chemotactic protein-1 (MCP-1) promoter polymorphism (A-2518G) with spontaneous bacterial peritonitis (SBP).

Analysis of monocyte chemotactic protein-1 gene polymorphism in patients with spontaneous bacterial peritonitis

AIM:To investigate a genetic polymorphism of the monocyte chemotactic protein-1 (MCP-1 ) gene in patients with spontaneous bacterial peritonitis (SBP).METHODS:MCP-1 genotyping was performed in 23 patients with SBP and 83 cirrhotic control patients with non-infected ascites.RESULTS:The frequency of carriers of the G-allele was lower in SBP patients but this difference did not reach statistical significance. However,in the subgroup of patients with alcoholic cirrhosis (n=80),carriers of the G-allele were significantly less frequent in SBP-patients (38.1%) than in cirrhotic controls (67.8%,P=0.021). CONCLUSION:In patients with alcoholic liver cirrhosis,the-2518 MCP-1 genotype AA is a risk factor for the development of SBP.

Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia

AIM: To investigate the expression and prognostic value of CCL2 in gastric cancer, as well as its relationship with tumor hypoxia.

Plasma monocyte chemotactic protein-1 remains elevated after minimally invasive colorectal cancer resection

AIM: To investigate plasma Monocyte Chemotactic Protein-1 levels preoperatively in colorectal cancer(CRC) and benign patients and postoperatively after CRC resection.METHODS: A plasma bank was screened for minimally invasive colorectal cancer resection(MICR) for CRC and benign disease(BEN) patients for whom preoperative, early postoperative, and 1 or more late postoperative samples(postoperative day 7-27) were available. Monocyte chemotactic protein-1(MCP-1) levels(pg/mL) were determined via enzyme linked immuno-absorbent assay. RESULTS: One hundred and two CRC and 86 BEN patients were studied. The CRC patient's median preoperative MCP-1 level(283.1, CI: 256.0, 294.3) was higher than the BEN group level(227.5, CI: 200.2, 245.2; P = 0.0004). Vs CRC preoperative levels, elevated MCP-1 plasma levels were found on postoperative day 1(446.3, CI: 418.0, 520.1), postoperative day 3(342.7, CI: 320.4, 377.4), postoperative day 7-13(326.5, CI: 299.4, 354.1), postoperative day 14-20(361.6, CI: 287.8, 407.9), and postoperative day 21-27(318.1, CI: 287.2, 371.6; P < 0.001 for all). CONCLUSION: Preoperative MCP-1 levels were higher in CRC patients(vs BEN). After MICR for CRC, MCP-1 levels were elevated for 1 mo and may promote angiogenesis, cancer recurrence and metastasis.

Effect of Monocyte Chemotactic Protein-1 on the Intraperitoneal Adhesion Formation

In order to study the role of monocyte chemotactic protein-1 (MCP-1) in the intra-peri- toneal adhesion formation, 23 infertile patients undergoing laparoscopic operation were divided into two groups: experimental group including 12 patients with intra-peritoneal adhesion and control group including 11 patients without intra-peritoneal adhesion. Peritoneal fluid (PF) and peritoneum were collected from these patients during laparoscopic examination. The expression levels of MCP-1 protein and MCP-1 mRNA were detected by using enzyme-linked immunosorbent assay (ELISA) and dot blot analysis method respectively. It was found that the levels of MCP-l protein in PF of the patients with peritoneal adhesion were significantly higher than in the control group (0.44±0. 11 ng/ ml vs 0. 19±0.09 ng/ml respectively, P<0. 01). The level of MCP-l mRNA in the peritoneum of the patients with peritoneal adhesion was significantly higher than in the control group (48. 61±3. 72 vs 19.87±2.54 respectively, P<0. 01). It was suggested that MCP-1 might play a role in the adhe- sion formation, and chemotactic cytokines expressing in the peritoneal mesothelial cells might be take part in the process.

Monocyte chemotactic protein-1 gene polymorphism and spontaneous bacterial peritonitis

I read with great interest the article by Gbele et al published in issue 44 of World J Gastroenterol 2009.The results of their study indicate that-2518 Monocyte chemotactic protein-1(MCP-1)genotype AA is a risk factor for spontaneous bacterial peritonitis in patients with alcoholic cirrhosis.However,there are some items that need to be discussed.

Monocyte chemotactic protein 1 increases homing of mesenchymal stem cell to injured myocardium and neovascularization following myocardial infarction

Objective：To investigate the effect of MCP-1 on mesenchymal stem cells（MSCs） homing to injured myocardium in a rat myocardial infarction（MI） model. Methods：Rat myocardial infarction model was established by permanent left anterior descending branch ligation. Mesenchymal stem cells from donor rats were cultured in IMDM and labeled with BrdU. The Rats were divided into two groups. Monocyte chemotactic protein I（MCP-1） expression were measured by in situ hybridization and immunohistochemistry in the sham operated or infarcted hearts at 1, 2, 4, 7, 14 and 28 days post operation in MCP-1 detection group. The rats were injected with MCP-1, anti-MCP-1 antibody or saline 4 days after myocardial infarction in intervention group. Then, a total of 5 × 10^6 cells in 2.5 ml of PBS were injected through the tail vein. The number of the labeled MSCs in the infarcted hearts was counted 3 days post injection. Cardiac function and blood vessel density were assessed 28 days post injection. Results：Self-generating MCP-1 expression was increased at the first day, peaked at the 7^th day and decreased thereafter post MI and remained unchanged in sham operated hearts. The MSCs enrichment in the host hearts were more abundant in the MI groups than that in the non-MI group（P= 0.000）, the MSCs enrichment in the host hearts were more abundant in the MCP-1 injected group than that in the anti-MCP-1 antibody and saline injected groups （P = 0.000）. Cardiac function was improved more in MCP-1 injected group than anti-MCP-1 antibody and saline injected groups（P= 0.000）. Neovascularization in MCP-1 injected group significantly increased compared with that of other groups（P = 0.000）. Conclusion： Myocardial MCP-1 expression was increased only in the early phase post MI. MCP-1 may enhance MSCs homing to the injured heart and improve cardiac function by promoting neovascularization.

Effects of Irbesartan and Metformin on tumor necrosis factor receptor and monocyte chemotactic protein 1 in patients with early diabetic nephropathy

Objective: To explore the effect of Irbesartan and Metformin on tumor necrosis factor receptor 1 and monocyte chemoattractant protein-1 in patients with early diabetic nephropathy. Methods: A total of 162 patients with early diabetic nephropathy who had been admitted to the Hospital between February 2017 and February 2018 were randomly assigned into a Metformin group, an Irbesartan group, and a combination therapy group. The Metformin group were treated with oral Metformin, those in the Irbesartan group were given oral Irbesartan for treatment, and the combination therapy group was treated with Metformin combined with Irbesartan. After 3 months of continuous treatment, the levels of sTNFR1, high-sensitivity C-reactive protein, monocyte chemoattractant protein-1, glucose metabolism index, proteinuria, and serum creatinine levels in the two groups were compared. Results:After treatment, the levels of sTNFR1, sICAM-1, hs-CRP, and MCP-1 in the three groups decreased compared with those before treatment, and the levels in the combination therapy group were all shown to be lower than those of the Metformin group and the Irbesartan group, with statistically significant differences (P<0.05). The levels of glycosylated hemoglobin and fasting blood glucose in the three groups were significantly lower than before treatment, and those in the combination therapy group were lower than the Metformin group and Irbesartan group, where the difference was statistically significant (P<0.05). The 24-hour urinary protein quantification, urinary albumin excretion rate, and serum creatinine in the combination therapy group were lower than those in the Metformin group and in the Irbesartan group, where the differences were statistically significant (P<0.05). Conclusion: The effects of metformin combined with irbesartan on early diabetic nephropathy patients were significant, which can effectively reduce the levels of serum sTNFR1 and MCP-1, relieve inflammation and improve glucose metabolism and proteinuria level.

Monocyte chemotactic protein-inducing protein 1 negatively regulating asthmatic airway inflammation and mucus hypersecretion involvingγ-aminobutyric acid type A receptor signaling pathway in vivo and in vitro

Background:Mounting evidence,consistent with our previous study,showed thatγ-aminobutyric acid type A receptor(GABAAR)played an indispensable role in airway inflammation and mucus hypersecretion in asthma.Monocyte chemotactic protein-inducing protein 1(MCPIP1)was a key negative regulator of inflammation.Recent studies showed that inflammation was largely suppressed by enhanced MCPIP1 expression in many inflammatory diseases.However,the role and potential mechanism of MCPIP1 in airway inflammation and mucus hypersecretion in asthma were still not well studied.This study was to explore the role of MCPIP1 in asthmatic airway inflammation and mucus hypersecretion in both mice and BEAS-2B cells,and its potential mechanism.Methods:In vivo,mice were sensitized and challenged by ovalbumin(OVA)to induce asthma.Airway inflammation and mucus secretion were analyzed.In vitro,BEAS-2B cells were chosen.Interleukin(IL)-13 was used to stimulate inflammation and mucus hypersecretion in cells.MCPIP1 Lentiviral vector(LA-MCPIP1)and plasmid-MCPIP1 were used to up-regulate MCPIP1 in lung and cells,respectively.MCP-1,thymic stromal lymphopoietin(TSLP),mucin 5AC(MUC5AC),MCPIP1,and GABAARβ2 expressions were measured in both lung and BEAS-2B cells.Immunofluorescence staining was performed to observe the expression of GABAARβ2 in cells.Results:MCPIP1 was up-regulated by LA-MCPIP1(P<0.001)and plasmid-MCPIP1(P<0.001)in lung and cells,respectively.OVA-induced airway inflammation and mucus hypersecretion,OVA-enhanced MCP-1,TSLP,MUC5AC,and GABAARβ2 expressions,and OVA-reduced MCPIP1 were significantly blunted by LA-MCPIP1 in mice(all P<0.001).IL-13-enhanced MCP-1,TSLP,MUC5AC,and GABAARβ2 expressions,and IL-13-reduced MCPIP1 were markedly abrogated by plasmid-MCPIP1 in BEAS-2B cells(all P<0.001).Conclusion:The results of this study suggested that OVA and IL-13-induced airway inflammation and mucus hypersecretion were negatively regulated by MCPIP1 in both lung and BEAS-2B cells,involving GABAAR signaling pathway.

Minimally modified low-density lipoprotein induces monocyte chemotactic protein-1 expression in vivo and a novel model for monocyte adhesion to arterial intima

ＯｂｊｅｃｔｉｖｅＴｏｔｅｓｔｗｈｅｔｈｅｒｍｉｎｉｍａｌｙｍｏｄｉｆｉｅｄｌｏｗｄｅｎｓｉｔｙｌｉｐｏｐｒｏｔｅｉｎ（ＭＭＬＤＬ）ｃａｎｓｔｉｍｕｌａｔｅｔｈｅａｒｔｅｒｉａｌｃｅｌｓｅｘｐｒｅｓｓｉｎｇＭＣＰ１ｉｎｖｉｖｏａｎｄｔｈｕｓｉｎ...

慢性肾小球肾炎患者MCP-1和sFlt-1表达与肾功能及预后的相关性研究

目的:分析慢性肾小球肾炎患者血清单核细胞趋化蛋白-1(MCP-1)和可溶性血管内皮细胞生长因子受体1(sFlt-1)水平变化及其与肾功能和预后的关系。方法:纳入2018-01—2020-03本院收治的慢性肾小球肾炎患者122例(研究组),选取同时期本院体检健康者128例(对照组)。研究组依据肾功能损害情况分为A组(肾功能正常16例)、B组(轻中度肾功能损害88例)、C组(重度肾功能损害18例);根据随访结局,将患者分为肾功能衰竭组(22例)和病情缓解组(100例)。采用酶联免疫吸附法(ELISA)检测受试者MCP-1、sFlt-1水平。采用全自动生化分析仪检测所有受试者血尿素氮(BUN)、血肌酐(Scr)水平,采用慢性肾脏疾病流行病学合作研究公式(CKD-EPI)估算肾小球滤过率(eGFR)。Pearson法分析MCP-1、sFlt-1与BUN、Scr、eGFR的相关性。采用受试者工作特征(ROC)曲线评价血清MCP-1、sFlt-1水平预测慢性肾小球肾炎患者预后的价值。结果:与对照组相比,研究组MCP-1、sFlt-1、BUN、Scr水平较高(P<0.05),eGFR较低(P<0.05)。C组BUN、Scr、MCP-1、sFlt-1水平明显高于A组、B组(P<0.05),B组BUN、Scr、MCP-1、sFlt-1水平明显高于A组(P<0.05)。Pearson相关性分析显示,MCP-1与BUN、Scr均呈正相关(P<0.05),与eGFR呈负相关(P<0.05),sFlt-1与BUN、Scr均呈正相关(P<0.05),与eGFR呈负相关(P<0.05)。与病情缓解组相比,肾功能衰竭组患者清中MCP-1、sFlt-1水平较高(P<0.05)。ROC分析显示,血清MCP-1、sFlt-1水平预测慢性肾小球肾炎患者预后的AUC分别为0.967、0.965,MCP-1联合sFlt-1预测慢性肾小球肾炎患者预后的AUC为0.984,灵敏度100.00%,特异度94.00%。结论:慢性肾小球肾炎患者血清MCP-1、sFlt-1水平明显上升,可作为患者预后评估的潜在生物学指标。

桂枝茯苓丸联合亮丙瑞林对子宫内膜异位症患者卵巢功能及血清VEGF和MCP-1的影响

目的:观察桂枝茯苓丸联合亮丙瑞林对子宫内膜异位症患者卵巢功能及血清血管内皮生长因子(VEGF)和单核细胞趋化蛋白-1(MCP-1)的影响。方法:选取佳木斯市中心医院2021年1月—2023年4月收治的87例子宫内膜异位症患者,按照随机数字表法分为研究组和对照组。对照组(n=43)采用亮丙瑞林治疗,研究组(n=44)在对照组的基础上联用桂枝茯苓丸。比较两组临床疗效、卵巢功能、免疫代谢、细胞因子及子宫动脉血流参数。结果:研究组治疗总有效率高于对照组,子宫动脉阻力指数(RI)、搏动指数(PI)及VEGF、MCP-1、卵泡刺激素(FSH)、黄体生成素(LH)均低于对照组,差异均有统计学意义(P<0.05)。结论:桂枝茯苓丸联合亮丙瑞林治疗子宫内膜异位症的效果较好,能够改善患者卵巢功能、免疫代谢。

木犀草素对神经性疼痛模型大鼠MCP-1/CCR2信号轴的影响

目的:探讨木犀草素调节单核细胞趋化蛋白-1(MCP-1)/CC趋化因子受体2(CCR2)信号轴,对神经性疼痛(NP)模型大鼠神经胶质细胞激活和免疫炎症的影响。方法:采用坐骨神经慢性压迫损伤法构建大鼠NP模型。将大鼠按随机数字表法分为模型组、阿魏酸钠组及木犀草素低、中、高剂量组,每组12只;另选择同期12只大鼠为假手术组。各组大鼠腹腔注射及灌胃相应药物,每天1次,连续14 d。测定大鼠机械性缩足反射阈值(MWT)和热刺激缩足反射潜伏期(TWL);实时荧光定量聚合酶链反应(qRT-PCR)及免疫组织化学法检测脊髓中胶质纤维酸性蛋白(GFAP)及小胶质细胞标志物离子钙接头蛋白分子1(Iba-1)mRNA及蛋白表达;流式细胞仪检测大鼠外周血中CD4^(+)、CD8^(+)水平;苏木素-伊红(HE)染色观察大鼠脊髓病理损伤情况;酶联免疫吸附试验(ELISA)检测脊髓中炎症因子白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、肿瘤坏死因子(TNF-α)水平;蛋白质印迹法(Western blotting)检测脊髓中MCP-1、CCR2蛋白表达。结果:与假手术组比较,模型组大鼠MWT、TWL、CD4^(+)T细胞比例及CD4^(+)/CD8^(+)比值降低,Iba-1、GFAP mRNA及蛋白表达、CD8^(+)T细胞比例、炎症因子水平(IL-6、IL-1β、TNF-α)、MCP-1及CCR2蛋白表达升高(P<0.05);与模型组比较,木犀草素低、中、高剂量组及阿魏酸钠组大鼠MWT、TWL、CD4^(+)T细胞比例及CD4^(+)/CD8^(+)比值升高,Iba-1、GFAP mRNA及蛋白表达、CD8^(+)T细胞比例、炎症因子水平(IL-6、IL-1β、TNF-α)、MCP-1及CCR2蛋白表达降低,且木犀草素作用效果呈剂量依赖性(P<0.05)。结论:木犀草素具有抗炎、增强免疫、抑制胶质细胞活化,缓解NP的作用,其作用机制可能与抑制MCP-1/CCR2信号轴的激活有关。

阻塞性睡眠呼吸暂停低通气综合征患者血清MCP-1、5-HT水平变化及意义

目的 探讨阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者血清单核细胞趋化蛋白-1(MCP-1)、5-羟色胺(5-HT)水平变化及意义。方法 选取107例OSAHS患者(OSAHS组),根据是否发生轻度认知障碍(MCI)分为MCI组(43例)和NMCI组(64例),另选取同期48名体检健康志愿者(对照组)。采用酶联免疫吸附法检测血清MCP-1、5-HT。通过多因素Logistic回归分析影响OSAHS患者MCI发生的因素,受试者工作特征(ROC)曲线分析血清MCP-1、5-HT水平对OSAHS患者MCI发生的预测价值。结果 与对照组比较,OSAHS组血清MCP-1水平升高,5-HT水平降低(P均<0.05)。107例OSAHS患者MCI发生率为40.19%(43/107)。与NMCI组比较,MCI组血清MCP-1水平升高,5-HT水平降低(P均<0.05)。年龄增加、病情程度重度和MCP-1升高为OSAHS患者MCI发生的独立危险因素,5-HT升高为独立保护因素(P均<0.05)。血清MCP-1、5-HT联合预测OSAHS患者MCI的曲线下面积为0.906,大于血清MCP-1、5-HT单独预测的0.805、0.828(P均<0.05)。结论 OSAHS患者血清MCP-1水平升高,5-HT水平降低,与MCI发生密切相关,血清MCP-1联合5-HT检测对预测OSAHS患者MCI发生有较高价值。

病毒性脑炎患儿脑脊液IP-10、MCP-1检测的临床意义

目的探讨病毒性脑炎患儿脑脊液干扰素诱导蛋白-10(IP-10)和单核细胞趋化蛋白-1(MCP-1)检测的临床意义。方法选取2019年7月—2020年12月邢台市人民医院病毒性脑炎患儿60例(病毒性脑炎组),其中轻症26例、重症34例,以排除颅内感染的发热患儿40例作为对照组。采用酶联免疫吸附试验检测脑脊液IP-10、MCP-1和肿瘤坏死因子-α(TNF-α)水平。采用Pearson相关分析评估IP-10、MCP-1水平与TNF-α水平的相关性。结果病毒性脑炎组脑脊液IP-10、MCP-1和TNF-α水平均显著高于对照组(P<0.001)。重症组脑脊液IP-10、MCP-1和TNF-α水平均显著高于轻症组(P<0.05)。Pearson相关分析结果显示,病毒性脑炎组脑脊液IP-10、MCP-1水平与TNF-α水平均呈正相关(r值分别为0.742、0.696,P<0.05)。结论IP-10和MCP-1与儿童病毒性脑炎的病情严重程度有关,可作为病情监测指标。

冠心病心绞痛患者血清内脏脂肪特异性丝氨酸蛋白酶抑制剂、不规则趋化因子、单核细胞趋化蛋白-1与心功能、心肌损伤指标相关性分析

目的:探讨冠心病(CHD)心绞痛患者血清内脏脂肪特异性丝氨酸蛋白酶抑制剂(Vaspin)、单核细胞趋化蛋白-1(MCP-1)、不规则趋化因子(Fractalkine)与心功能、心肌损伤指标的相关性。方法:选取150例CHD心绞痛患者作为观察组(不稳定型心绞痛患者64例为A组、稳定型心绞痛患者86例为B组),同期收治的164例非CHD患者为C组。比较三组血清Fractalkine、Vaspin、MCP-1水平、心功能指标及心肌损伤指标,相关性采用Pearson相关性分析。结果:A组血清Vaspin水平低于B组、C组,且与C组比较,B组更低;A组血清Fractalkine、MCP-1水平高于B组、C组,且与C组比较,B组更高(均P<0.05)。A组左心室射血分数(LVEF)、左心室短轴缩短率(FS)低于B组、C组,且与C组比较,B组更低;A组左心室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)高于B组、C组,且与C组比较,B组更高(均P<0.05)。A组各心肌损伤指标水平均高于B组、C组,且与C组比较,B组更高(均P<0.05)。Pearson相关性分析:CHD心绞痛患者血清Vaspins水平与LVEF、FS成正比;血清Vaspins水平与LVEDD、LVESD、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)、心型脂肪酸结合蛋白(H-FABP)成反比;血清Fractalkine、MCP-1与LVEF、FS成反比;血清Fractalkine、MCP-1与LVEDD、LVESD、CK、CK-MB、cTnI、H-FABP成正比(均P<0.05)。结论:随着CHD心绞痛患者病情加重,患者心功能及心肌损伤越严重,且患者血清Vaspins、Fractalkine、MCP-1与患者心功能及心肌损伤具有密切联系,临床可根据其水平变化评估病情进展情况。

MP感染合并哮喘患儿血清miR-424-5p、MCP-1、TLR4水平联合检测预测预后的效能

目的探讨肺炎支原体(MP)感染合并哮喘患儿血清miR-424-5p、单核细胞趋化蛋白-1(MCP-1)、Toll样受体4(TLR4)水平联合检测预测预后的效能。方法回顾性选取2021年8月至2023年8月濮阳市人民医院收治的107例MP感染合并哮喘患儿作为研究对象,所有患儿均给予对症治疗,根据6个月预后分为预后良好组86例和预后不良组21例。比较两组患儿的基线资料和血清miR-424-5p、MCP-1、TLR4水平,采用Logistic回归分析各血清指标对预后的影响,绘制受试者工作特征(ROC)曲线及曲线下面积(AUC)分析血清miR-424-5p、MCP-1、TLR4对预后的预测效能。结果两组患儿的病程、发热天数、呼吸道感染史比较差异均有统计学意义(P<0.05);预后不良组患儿的血清miR-424-5p、MCP-1、TLR4水平分别为1.56±0.41、(84.29±15.19)μg/L、(95.21±13.52)ng/mL,明显高于预后良好组的1.23±0.33、(70.38±11.36)μg/L、(83.10±10.17)ng/mL,差异均有统计学意义(P<0.05);校正前Logistic回归分析结果显示,病程、发热天数、呼吸道感染史、血清miR-424-5p、MCP-1、TLR4均是MP感染合并哮喘患儿预后的独立影响因素(P<0.05),校正后Logistic回归分析结果显示,血清miR-424-5p、MCP-1、TLR4仍是MP感染合并哮喘患儿预后的独立影响因素(P<0.05);ROC曲线结果显示,血清miR-424-5p、MCP-1、TLR4联合检测预测MP感染合并哮喘患儿预后的AUC为0.900,优于各血清指标单独预测。结论MP感染合并哮喘患儿血清mi R-424-5p、MCP-1、TLR4与预后密切相关,三者联合检测预测MP感染合并哮喘患儿预后具有良好的参考价值。

全血NPM1、MCP-1和肠道菌群与胃癌进展及预后相关

目的探讨全血核仁磷酸蛋白1(NPM1)、单核细胞趋化蛋白-1(MCP-1)、肠道菌群与胃癌进展及预后的相关性。方法选取2018年5月至2020年5月在南阳市第二人民医院收治的胃癌患者120例作为胃癌组,另选取同期胃镜检查胃良性病变患者120例作为胃良性病变组,再选取同期健康体检者120例作为对照组。RT-qPCR检测NPM1 mRNA、MCP-1 mRNA转录水平;用MicroScan微生物鉴定分析系统检测肠道菌群;用Pearson法分析血清NPM1、MCP-1和肠道菌群的相关性;用多因素COX回归分析胃癌患者预后的影响因素。结果对照组、胃良性病变组和胃癌组NPM1 mRNA、双歧杆菌和乳酸杆菌水平依次降低(P<0.05),而MCP-1 mRNA、肠球菌和大肠埃希菌水平依次升高(P<0.05)。胃癌Ⅲ~Ⅳ期的NPM1 mRNA、双歧杆菌和乳酸杆菌水平显著低于Ⅰ~Ⅱ期(P<0.05),MCP-1 mRNA、肠球菌和大肠埃希菌水平显著高于Ⅰ~Ⅱ期(P<0.05)。Pearson相关性分析表明,胃癌患者NPM1 mRNA与MCP-1 mRNA水平呈负相关(P<0.05),NPM1 mRNA与双歧杆菌和乳酸杆菌呈正相关(P<0.05),与肠球菌和大肠埃希菌呈负相关(P<0.05),MCP-1 mRNA与与双歧杆菌和乳酸杆菌呈负相关(P<0.05),与肠球菌和大肠埃希菌呈正相关(P<0.05)。预后不良组NPM1 mRNA、双歧杆菌和乳酸杆菌水平显著低于预后良好组(P<0.05),MCP-1 mRNA、肠球菌和大肠埃希菌水平显著高于预后良好组(P<0.05)。COX回归分析表明,MCP-1 mRNA、肠球菌和大肠埃希菌是影响胃癌患者预后的危险因素(P<0.05),NPM1 mRNA、双歧杆菌、乳酸杆菌是保护因素(P<0.05)。结论胃癌患者中NPM1、肠道双歧杆菌和乳酸杆菌水平降低,MCP-1、肠球菌和大肠埃希菌水平升高,其均与胃癌进展和预后密切相关。

血清MCP-1水平及外周血Th17/Treg平衡与老年COPD并发全身炎症反应综合征的关系

目的探讨血清单核细胞趋化蛋白-1(MCP-1)水平及外周血辅助性T细胞17(Th17)/调节性T细胞(Treg)平衡与老年慢性阻塞性肺疾病(COPD)并发全身炎症反应综合征(SIRS)的关系。方法选取82例老年COPD合并SIRS患者(SIRS组),以1∶1比例对照选取单纯老年COPD患者(非SIRS组)。采用酶联免疫吸附法与流式细胞术检测血清MCP-1与外周血Th17、Treg比例。通过多因素Logistic回归分析老年COPD并发SIRS的影响因素,受试者工作特征(ROC)曲线分析血清MCP-1水平和外周血Th17/Treg对老年COPD并发SIRS的预测价值。结果与非SIRS组比较,SIRS组血清MCP-1和外周血Th17、Th17/Treg高,外周血Treg比例低(P<0.05)。Th17高(OR=3.640,95%CI:1.929~6.867)、MCP-1高(OR=1.035,95%CI:1.016~1.054)、Th17/Treg高(OR=3.612,95%CI:1.835~7.107)为老年COPD并发SIRS的独立危险因素,Treg高(OR=0.651,95%CI:0.467~0.907)为独立保护因素(P<0.05)。血清MCP-1水平联合外周血Th17/Treg预测老年COPD并发SIRS的曲线下面积为0.890(95%CI:0.832~0.934),大于血清MCP-1水平、外周血Th17/Treg单独预测(P均<0.05)。结论血清MCP-1水平升高和Th17/Treg失衡与老年COPD并发SIRS独立相关,血清MCP-1水平联合外周血Th17/Treg检测对老年COPD并发SIRS有较高的预测价值。